TrialJournal for immunotherapy of cancer2022

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.

Toni K Choueiri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.